Determination of estramustine phosphate and its metabolites estromustine, estramustine, estrone and estradiol in human plasma by liquid chromatography with fluorescence detection and gas chromatography with nitrogen-phosphorus and mass spectrometric detection

被引:23
作者
Edman, K [1 ]
Svensson, L [1 ]
Eriksson, B [1 ]
Gunnarsson, PO [1 ]
机构
[1] Act Biotech Res AB, S-22007 Lund, Sweden
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2000年 / 738卷 / 02期
关键词
estramustine phosphate; estromustine; estrone; estradiol; estramustine;
D O I
10.1016/S0378-4347(99)00526-5
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Bioanalytical methods for the determination of estramustine phosphate by liquid chromatography and its four main metabolites estromustine, estramustine, estrone and estradiol by gas chromatography are described. For the estramustine phosphate assay the plasma was purified by protein precipitation followed by a C-18 solid-phase extraction. For the metabolite assay the plasma samples were purified by a C-18 solid-phase and liquid-liquid extraction procedure and derivatised by silanization. Thereafter, estramustine and estromustine were quantified by gas chromatography with nitrogen-phosphorus detection and estradiol and estrone were quantified by gas chromatography with selected ion monitoring. The methods were validated with respect to linearity, selectivity, precision, accuracy, limit of quantitation, limit of detection, recovery and stability. The limit of quantitation was 2.3 mu mol/l for estramustine phosphate, 30 nmol/l for estromustine and estramustine, 12 nmol/l for estrone and 8 nmol/l for estradiol. The results showed good precision and accuracy for estramustine phosphate and the four metabolites. The intermediate precision was 6.2-13.5% (C.V.) and the accuracy was 91.8-103.9%. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:267 / 279
页数:13
相关论文
共 22 条
[1]  
ANDERSSON S B, 1981, European Journal of Drug Metabolism and Pharmacokinetics, V6, P149
[2]  
ANDERSSON SB, 1982, ACTA PHARM SUEC, V19, P1
[3]   MECHANISMS OF ACTION AND CLINICAL USES OF ESTRAMUSTINE [J].
BENSON, R ;
HARTLEYASP, B .
CANCER INVESTIGATION, 1990, 8 (3-4) :375-380
[4]  
BERGENHEIM AT, 1994, INT J ONCOL, V5, P293
[5]   UPTAKE AND RETENTION OF ESTRAMUSTINE AND THE PRESENCE OF ESTRAMUSTINE BINDING-PROTEIN IN MALIGNANT BRAIN-TUMORS IN HUMANS [J].
BERGENHEIM, AT ;
GUNNARSSON, PO ;
EDMAN, K ;
VONSCHOULTZ, E ;
HARIZ, MI ;
HENRIKSSON, R .
BRITISH JOURNAL OF CANCER, 1993, 67 (02) :358-361
[6]   DETERMINATION OF ESTRAMUSTINE AND ITS 17-KETO METABOLITE IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
BROOKS, MA ;
DIXON, R .
JOURNAL OF CHROMATOGRAPHY, 1980, 182 (3-4) :387-394
[7]  
DAHLLOF B, 1993, CANCER RES, V53, P4573
[8]  
DIXON R, 1980, RES COMMUN CHEM PATH, V27, P17
[9]   EVIDENCE FOR A NON-ESTROGENIC CYTOSTATIC EFFECT OF ESTRAMUSTINE ON HUMAN PROSTATIC-CARCINOMA CELLS INVIVO [J].
EKLOV, S ;
NILSSON, S ;
LARSON, A ;
BJORK, P ;
HARTLEYASP, B .
PROSTATE, 1992, 20 (01) :43-50
[10]  
FORSGREN B, 1978, ACTA PHARM SUEC, V15, P200